Alkeus Pharmaceuticals Receives Orphan Drug Designation From Japan's Ministry Of Health, Labour, And Welfare For Oral Gildeuretinol To Treat Stargardt Disease
Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan
Alkeus got special permission from Japan to test a medicine for a rare eye disease, which could mean fewer rules to follow and more chances to help patients there. This shows the company is moving forward with its work, though it's still early and the medicine needs to prove it actually works.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.